About this trial

This study aims to evaluate whether microbiological testing of the perfusion fluid used to transport transplanted organs can help predict the development of infections in liver and kidney transplant recipients, including possible donor-derived infections (infections transmitted from the donor organ).

The study will include all liver and kidney transplant recipients with available perfusion fluid culture results from 2021 until the start of the study (retrospective phase) and for two years after study initiation (prospective phase).

The study will assess how often high-risk microorganisms are identified in perfusion fluid, whether these findings are associated with complications or infections in recipients, and whether they affect patient outcomes, including mortality.

Eligibility criteria

Qualifiers

Adult patients (≥18 years old) undergoing liver or kidney transplantation at IRCCS AOUBO clinical center during the specified study periods

Availability of graft preservation fluid culture results

Signed informed consent

Disqualifiers

None

Trial design

Treatments tested in this trial

  • Not listed

Trial groups

1,400 Participants
are grouped into 1 trial group

Locations

1
IRCCS Azienda Ospedaliero-Universitaria di Bologna40128, BolognaItaly, Italy

Sponsors and collaborators

IRCCS Azienda Ospedaliero-Universitaria di Bologna

Lead sponsor